University of Notre Dame
Trial Pipeline
Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment
NCT07342504
Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents
NCT05602779
An Evidence-based Family Support Program for Parents and Children in Palestine: a Theory-based Intervention
NCT05706376
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
NCT04980794
Evaluation of SUMMIT BRUSH in Treatment of Blepharitis
NCT04603222
Families of Youth with Developmental Disabilities: a Theory-Based Intervention
NCT03495440
Efficacy of Family Programs for Improving Child and Family Health and Development
NCT03367845
Therapeutic Areas
What the Pipeline for University of Notre Dame Shows
According to the ClinicalTrials.gov registry, University of Notre Dame is linked to 38 US clinical trials across every stage of research activity. Of those, 37 studies are currently recruiting — about 97% of the sponsor's indexed portfolio — and 0 are already marked complete, representing roughly 0% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for University of Notre Dame reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for University of Notre Dame is Behavior, Infant with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.